Treatment options for wastewater effluents from pharmaceutical companies
In recent years, concerns about the occurrence and fate of active pharmaceutical ingredients, solvents, intermediates and raw materials that could be present in water and wastewater including pharmaceutical industry wastewater has gained increasing attention. Traditional wastewater treatment methods...
Gespeichert in:
Veröffentlicht in: | International journal of environmental science and technology (Tehran) 2011-06, Vol.8 (3), p.649-666 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In recent years, concerns about the occurrence and fate of active
pharmaceutical ingredients, solvents, intermediates and raw materials
that could be present in water and wastewater including pharmaceutical
industry wastewater has gained increasing attention. Traditional
wastewater treatment methods, such as activated sludge, are not
sufficient for the complete removal of active pharmaceutical
ingredients and other wastewater constituents from these waters. As a
result, complementary treatment methods such as membrane filtration,
reverse osmosis and activated carbon are often used in conjunction with
the traditional methods for treatment of industrial wastewater. Most of
the literature published to date has been on the treatment of municipal
wastewater. However, there is a growing body of research that looks at
the presence of active pharmaceutical ingredients in industrial
wastewater, the treatment of these wastewaters and the removal rates.
This article, reviews these treatment methods and includes both
traditional methods and advanced oxidation processes. The paper
concludes by showing that the problem of pharmaceuticals in wastewaters
cannot be solved merely by adopting end of pipe measures. At source
measures, such as replacement of critical chemicals, reduction in raw
material consumption should continue to be pursued as the top priority. |
---|---|
ISSN: | 1735-1472 1735-2630 |
DOI: | 10.1007/BF03326250 |